Gypenoside XVII
(Synonyms: 七叶胆苷XVII,Gynosaponin S) 目录号 : GN10566A saponin with diverse biological activities
Cas No.:80321-69-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: |
For the establishment of an Ox-LDL-induced apoptosis model and measurement of Gypenoside XVII’s protective effect, the HUVECs are seeded in 96-well plates at a density of 105 cells per mL and grown for 24 h. Then, the HUVECs are pretreated with Gypenoside XVII (6.25, 12, 25, 50, 100 μg/mL) for 12 h in serum-free endothelial cell basal medium, followed by incubation with Ox-LDL (100 μg/mL, 24 h) which does not have Gypenoside XVII. After 24 h, the treated HUVECs are incubated with 5 mg/mL MTT in fresh medium for an additional 4 h. Absorbance is measured at 570 nm using a plate reader[1]. |
Animal experiment: |
Mice[1]A total of 42 ApoE-/- mice and 12 male C57BL/6J mice with the same age and body weight (approximately 20 g in body weight and 6 weeks old) are randomly divided into 4 groups (12 mice for each group) and orally administered the following once a: C57 control group (vehicle; 0.5% sodium carboxymethylcellulose, CMC-Na); ApoE-/- model group (vehicle; 0.5% CMC-Na); ApoE-/-+Gypenoside XVII group (Gypenoside XVII, 50 mg/kg via i.g. ); ApoE-/-+probucol group (Probucol, 2 mg/kg via i.g.). Probucol is an antioxidant drug used as a positive control. After two weeks of acclimatization, all the mice are fed a high-fat diet including 0.3% cholesterol and 20% pork fat for 10 weeks. They are maintained in pathogen-free conditions at approximately 22±1°C on a 12 h light-dark cycle with free access to food and water. The body weights are determined every two weeks. After 10 weeks of the treatments, all animals are anesthetized with pentobarbital sodium and killed after being deprived of food overnight. Serum is immediately separated from blood samples by centrifugation at 3600 rpm for 15 min, and the tissue samples (heart and aorta) are rapidly removed and frozen in -8°C. |
References: [1]. Yang K, et al. Gypenoside XVII Prevents Atherosclerosis by Attenuating Endothelial Apoptosis and Oxidative Stress: Insight into the ERα-Mediated PI3K/Akt Pathway. Int J Mol Sci. 2017 Feb 9;18(2). pii: E77. |
Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.
The ability of Gypenoside XVII (GP-17) to prevent Ox-LDL-induced cytotoxicity is detected by cell viability assays. Gypenoside XVII does not demonstrate any cytotoxicity in HUVECs. Gypenoside XVII can protect HUVECs against Ox-LDL-induced apoptosis. Gypenoside XVII dose-dependently mitigates the toxic effect of Ox-LDL on HUVEC viability. The viability of HUVECs is significantly higher than that of other groups at 50 μg/mL Gypenoside XVII [1].
Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE-/- mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE-/- model group[1].
References:
[1]. Yang K, et al. Gypenoside XVII Prevents Atherosclerosis by Attenuating Endothelial Apoptosis and Oxidative Stress: Insight into the ERα-Mediated PI3K/Akt Pathway. Int J Mol Sci. 2017 Feb 9;18(2). pii: E77.
Cas No. | 80321-69-3 | SDF | |
别名 | 七叶胆苷XVII,Gynosaponin S | ||
化学名 | Gypenoside XVII | ||
Canonical SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)C)O)C)OC6C(C(C(C(O6)COC7C(C(C(C(O7)CO)O)O)O)O)O)O)C | ||
分子式 | C48H82O18 | 分子量 | 947.15 |
溶解度 | 储存条件 | 4°C, protect from light | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.0558 mL | 5.279 mL | 10.558 mL |
5 mM | 0.2112 mL | 1.0558 mL | 2.1116 mL |
10 mM | 0.1056 mL | 0.5279 mL | 1.0558 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。